Finally, drugs that have been overwhelmingly developed for other purposes but have shown effects on BAT activity: drugs for the treatment of obesity and/or type 2 diabetes mellitus (T2DM): metformin, thiazolidinediones (TZDs), glucagon-like peptide (GLP)-1 receptor agonists (GLP-1RA), sibutramine; drugs for the treatment of overactive bladder: beta3-adrenoreceptor (AR) agonists (beta3-ARa) (mirabegron). This evidence concerns the gene GLP1R and type 2 diabetes mellitus.